CLINICAL TRIALS PROFILE FOR IMBRUVICA

505(b)(2) Clinical Trials for IMBRUVICA

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02841150 ↗	Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules	Completed	Janssen Research & Development, LLC	Phase 1	2016-06-01	The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.
New Formulation	NCT02877225 ↗	Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule	Completed	Janssen Research & Development, LLC	Phase 1	2016-08-29	The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.

All Clinical Trials for IMBRUVICA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01779791 ↗	A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma	Completed	Pharmacyclics LLC.	Phase 2	2013-04-17	The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01779791 ↗	A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma	Completed	Janssen Research & Development, LLC	Phase 2	2013-04-17	The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01829568 ↗	Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma	Active, not recruiting	Celgene Corporation	Phase 1	2013-06-21	This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
NCT01829568 ↗	Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2013-06-21	This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
NCT01841723 ↗	Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2013-04-01	This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Conditions for IMBRUVICA

Condition Name

Condition Name for IMBRUVICA
Intervention	Trials
Chronic Lymphocytic Leukemia	30
Mantle Cell Lymphoma	16
Small Lymphocytic Lymphoma	15
Refractory Chronic Lymphocytic Leukemia	12

Condition MeSH

Condition MeSH for IMBRUVICA
Intervention	Trials
Lymphoma	78
Leukemia, Lymphoid	57
Leukemia, Lymphocytic, Chronic, B-Cell	55
Leukemia	54

Clinical Trial Locations for IMBRUVICA

Trials by Country

Trials by Country for IMBRUVICA
Location	Trials
United States	590
Japan	35
Spain	29
Australia	22
Italy	18

Trials by US State

Trials by US State for IMBRUVICA
Location	Trials
Texas	40
Ohio	38
California	36
New York	28
Massachusetts	27

Clinical Trial Progress for IMBRUVICA

Clinical Trial Phase

Clinical Trial Phase for IMBRUVICA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	15
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for IMBRUVICA
Clinical Trial Phase	Trials
Active, not recruiting	55
Recruiting	44
Completed	23

Clinical Trial Sponsors for IMBRUVICA

Sponsor Name

Sponsor Name for IMBRUVICA
Sponsor	Trials
National Cancer Institute (NCI)	59
Pharmacyclics LLC.	30
M.D. Anderson Cancer Center	21

Sponsor Type

Sponsor Type for IMBRUVICA
Sponsor	Trials
Other	135
Industry	119
NIH	61

IMBRUVICA Market Analysis and Financial Projection

Last updated: February 4, 2026

What is the current status of clinical trials for IMBRUVICA?

IBRUVICA (ibrutinib) is a BTK inhibitor developed by Pharmacyclics (acquired by AbbVie in 2015) for hematological malignancies. As of late 2022, it has completed multiple phases of clinical trials with broad indications approvals.

Ongoing Clinical Trials

• Leukemia and Lymphoma: Several phase 3 trials assess its efficacy in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Key studies include E1912 (comparing ibrutinib plus rituximab vs. chemoimmunotherapy) and the RESONATE trial.
• Mantle Cell Lymphoma (MCL): Phase 2 trials evaluate long-term safety and effectiveness of IMBRUVICA in relapsed/refractory MCL.
• Waldenström's Macroglobulinemia (WM): Multiple phase 3 studies are underway or completed, including real-world data gathering.
• Other Hematological Malignancies: Trials examine combinations with other targeted therapies for conditions like marginal zone lymphoma and diffuse large B-cell lymphoma.

Approvals and Label

• FDA (2016): Approved for CLL/SLL, MCL, WM, and other indications.
• EMA & Other Regulators: Approvals align with FDA indications, expanding access globally.

How does the market currently look for IMBRUVICA?

Market Size and Revenue

• Global Sales: Estimated $6.4 billion in 2022 (Evaluate Pharma), with a compound annual growth rate (CAGR) of approximately 12% from 2018 to 2022.
• Leading Markets: United States accounts for over 70% of sales; Europe follows, with emerging Asian markets showing early adoption.

Market Penetration

• Indications: Approved for multiple hematologic cancers, leading to broad utilization.
• Competitive Position: Dominates BTK inhibitors, with key competitors including Zydelig (idelalisib) and newer agents like CAR-T therapies for certain indications.

Key Market Drivers

• Increasing prevalence of hematological malignancies.
• Growing adoption of targeted therapies.
• Extended treatment durations improve revenue stability.

Market Challenges

• Competition from second-generation BTK inhibitors like acalabrutinib and zanubrutinib.
• Patent expirations looming, risking generic entry post-2027.
• Cost pressures and payer reimbursement policies.

What is the market projection for IMBRUVICA over the next five years?

Revenue Outlook

• Forecasted Revenue: Expected to reach approximately $8.2 billion by 2027, with a CAGR of about 8% from 2023 to 2027.
• Sources of Growth: Expansion into new indications, increased adoption in Asia-Pacific, and potential combination therapies.

Regulatory and Development Outlook

• Anticipated approvals for additional indications such as chronic graft-versus-host disease and other rare hematologic conditions.
• Continued clinical trials exploring combination regimens, which could expand use cases.

Risks to Market Projection

• Emergence of competing therapies offering improved safety profiles or efficacy.
• Changes in reimbursement policies affecting utilization.
• Potential delays in regulatory approvals for new indications.

How does IMBRUVICA compare to competitors?

Aspect	IMBRUVICA	Acalabrutinib	Zanuubrutinib
Development Company	AbbVie, Janssen	AstraZeneca	BeiGene
Approved Indications	CLL, MCL, WM, others	CLL, MCL	CLL, MCL
Patent Expiry	2027 (US)	2028	2030
Efficacy	Proven across multiple indications	Similar efficacy, potentially fewer off-target effects	Similar efficacy, different toxicity profile

Key takeaways

• IMBRUVICA remains a leading therapy in hematological cancers with broad approval.
• Clinical trials continue, with several promising indications and combination strategies in Phase 2/3.
• Sales are expected to grow modestly, driven by expanded indications and geographic reach.
• Competitive landscape stiffens with newer BTK inhibitors offering potential advantages.
• Patent expirations forecast a potential decline in revenue post-2027, unless new indications or formulations are approved.

FAQs

1. What are the main indications for IMBRUVICA's current approval?

IMBRUVICA is approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, and chronic graft-versus-host disease.

2. Which ongoing clinical trials could impact IMBRUVICA’s approval pipeline?

Trials exploring combinations with monoclonal antibodies, CAR-T therapy, and newer agents for indications like marginal zone lymphoma and diffuse large B-cell lymphoma are ongoing and may lead to expanded uses.

3. How does the patent expiry affect IMBRUVICA’s market?

Patent expiration is projected around 2027 in the US. Generic versions could reduce sales, although biosimilars and new indications may mitigate revenue loss.

4. How competitive is IMBRUVICA versus emerging therapies?

Second-generation BTK inhibitors like acalabrutinib and zanubrutinib have better selectivity profiles and fewer side effects, positioning them as potential rivals, especially in second-line settings.

5. What factors could influence future growth for IMBRUVICA?

Regulatory approvals for new indications, successful combination therapies, expansion into emerging markets, and price regulation are primary factors influencing growth.

---

Citations:

1. Evaluate Pharma. (2022). "Imbruvica market analysis."
2. FDA. (2016). "Imbruvica approval details."
3. ClinicalTrials.gov. (2022). "Ongoing IMBRUVICA trials."
4. IQVIA. (2022). "Hematology market insights."
5. Genetic Engineering & Biotechnology News. (2022). "BTK inhibitors and competitive landscape."